885 shares in IQVIA Holdings Inc. (NYSE:IQV) acquired by Hantz Financial Services Inc.

Hantz Financial Services Inc. bought a new position in IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 885 shares of the medical research company’s stock, valued at approximately $187,000.

A number of other hedge funds have also modified their holdings of the company. Jennison Associates LLC boosted its position in shares of IQVIA by 7.3% in the first quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock worth $35,636,000 after acquiring an additional 9,578 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of IQVIA by 4.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after acquiring an additional 93,194 shares in the last quarter. Cadian Capital Management LP purchased a new stake in shares of IQVIA in the fourth quarter valued at about $70,108,000. Nomura Holdings Inc. purchased a new stake in shares of IQVIA in the fourth quarter valued at about $857,000. Finally, PGGM Investments boosted its position in shares of IQVIA by 55.8% in the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after acquiring an additional 4,326 shares in the last quarter. 89.62% of shares are owned by institutional investors and hedge funds.

The Wall Street analyst weighs in

Several research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. UBS Group upped their target price on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Robert W. Baird upped their target price on shares of IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a report on Tuesday, July 23rd. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, Truist Financial upped their target price on shares of IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Moderate Buy” and a consensus price target of $265.67, based on data from MarketBeat.

Read our latest research report on IQV

IQVIA stock down 0.3%

Shares of NYSE:IQV opened at $251.55 on Monday. The company has a current ratio of 0.85, a quick ratio of 0.85, and a debt-to-equity ratio of 1.80. The company has a fifty day simple moving average of $231.33 and a 200 day simple moving average of $234.33. The firm has a market cap of $45.86 billion, a PE ratio of 34.36, a price-to-earnings-growth ratio of 2.37 and a beta of 1.49. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73.

IQVIA (NYSE:IQV – Get Your Free Report ) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s revenue was up 2.3% compared to the same quarter last year. In the same quarter last year, the company earned $2.22 per share. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.24 EPS for the current fiscal year.

Insider buying and selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC’s website. Insiders own 1.60% of the company’s shares.

About IQVIA

(Free report)

IQVIA Holdings Inc is committed to providing advanced analytics, technology solutions and clinical research services to the life sciences industry in the Americas, Europe, Africa and Asia-Pacific. It operates through three segments: Technology Solutions and Analytics, Research and Development Solutions, and Medical Solutions and Contract Sales.

Further reading

Want to see what other hedge funds hold IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for IQVIA Holdings Inc. (NYSE:IQV – Free Report).

Get news and reviews for IQVIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IQVIA and related companies with MarketBeat.com’s FREE daily email newsletter.